SEC Form 4/A · accession 0001179110-16-029616
CATABASIS PHARMACEUTICALS INC · CATB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
This is an amendment (Form 4/A). It replaces an earlier filing for the same period.
Reporting owner
Jill C. Milne
Officer — CEO and President · Director
Period of report
Sep 8, 2016
Accepted (ET)
Sep 13, 2016 · 5:24 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001454789
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1,F2 | $4.31 | Sep 8, 2016 | A | 45,000 | A | — | Sep 7, 2026 | Common Stock | 45,000 | 45,000 | D |
Explanation of responses
- F1This Form 4/A is being filed to correct the stated Conversion or Exercise Price of Derivative Security. The correct Exercise Price of the Derivative Security is $4.31 and was previously stated as $4.30.
- F2The option was granted on September 8, 2016 and is subject to vesting over a four year period, with 25% of the shares vesting on the first anniversary of September 8, 2016 and the reminder vesting over the ensuing three years at a rate of 2.0833% per month.